文献速递糖尿病性腺与生殖内分泌

激素因素与AGEs均不能解释老年糖尿病男性前列腺癌风险降低

Neither Hormonal Factors Nor AGEs Explain Lower Prostate Cancer Risk in Older Men With Diabetes Mellitus.
PubMed 文献 · J Clin Endocrinol Metab · 2019-01-01

在3149名男性中随访12年的纵向队列研究显示,糖尿病与前列腺癌风险降低相关(完全校正亚风险比0.63,95%CI 0.43-0.92,P=0.017)。校正性激素、IGF1及其结合蛋白、葡萄糖或CML后该关联均未改变。

要点

  • 糖尿病与前列腺癌风险降低独立相关,校正后亚风险比0.63。
  • 性激素、IGF1、葡萄糖及CML均未介导该负相关。
  • CML与前列腺癌风险无关,校正CML不改变糖尿病与前列腺癌的关联。

核心结论

  • 性激素、IGF1、葡萄糖及CML水平的变化均不能解释糖尿病与前列腺癌风险的负相关。
  • 需进一步研究探讨该关联的潜在原因。

研究设计与样本

  • 纵向队列研究,纳入3149名男性,随访12年。
  • 采用比例风险竞争风险分析评估基线糖尿病与前列腺癌发病率的关联。
  • 检测基线激素、葡萄糖及羧甲基赖氨酸(CML)水平作为潜在中介因子。

主要发现

  • 糖尿病与较低的前列腺癌风险相关(完全校正亚风险比0.63;95%CI 0.43-0.92;P=0.017)。
  • 校正睾酮、DHT、雌二醇或SHBG后该关联不变。
  • 加入IGF1或其结合蛋白1和3,或葡萄糖后该关联不变。
  • CML与前列腺癌风险无关,完全校正模型中加入CML后糖尿病与前列腺癌的负关联不变。

关键数值与推荐

  • 糖尿病与前列腺癌风险的完全校正亚风险比为0.63(95%CI 0.43-0.92;P=0.017)。
  • 校正性激素、IGF1、葡萄糖或CML后,该亚风险比均未发生改变。

临床怎么用

  • 临床中不应以性激素、IGF1、血糖或AGEs水平解释糖尿病男性前列腺癌风险降低。
  • 对糖尿病男性进行前列腺癌风险评估时,需考虑糖尿病本身与风险降低的独立关联。

局限性

  • 原文未报告具体局限性内容。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

CONTEXT: Diabetes mellitus is conventionally associated with an increased risk of cancer; however, inverse associations of diabetes with prostate cancer are well described. Mechanisms are unclear, although hormonal factors, including alterations in sex hormone and IGF1 concentrations due to metabolic disturbances, have been hypothesized to play a role. OBJECTIVE: To assess sex hormones, IGF1, glucose, and advanced glycation end products (AGEs) as potential mediators of the association between diabetes mellitus and prostate cancer. DESIGN AND PARTICIPANTS: Longitudinal cohort study. The association of baseline diabetes with prostate cancer incidence was assessed using proportional hazards competing risks analysis in 3149 men followed for 12 years. Baseline hormone, glucose, and carboxymethyllysine (CML) levels were examined as potential mediators of this association. RESULTS: Diabetes was associated with a lower prostate cancer risk (fully adjusted subhazard ratio, 0.63; 95% CI, 0.43 to 0.92; P = 0.017). This association was unchanged after accounting for testosterone, DHT, estradiol, or SHBG. Similarly, the addition of IGF1 or its binding proteins 1 and 3, or glucose, did not alter this association. CML was not associated with the risk of prostate cancer, and additional correction for CML in the fully adjusted model did not alter the inverse association of diabetes and prostate cancer risk. CONCLUSIONS: In this study, alterations in sex hormone, IGF1, glucose, and CML levels did not account for the inverse association of diabetes and prostate cancer risk. Further studies are required to provide more insight into underlying causes of this association.

来源:J Clin Endocrinol Metab,查看原文。版权归原作者所有。

引用

  1. Chan YX, Alfonso H, Fegan PG, et al. Neither Hormonal Factors Nor AGEs Explain Lower Prostate Cancer Risk in Older Men With Diabetes Mellitus. J Clin Endocrinol Metab. 2019. PMID: 31504635. doi:10.1210/jc.2019-01142

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。